NASDAQ: ELDN - Eledon Pharmaceuticals, Inc.

Yield per half year: +1.71%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Eledon Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc.

more details
and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2014-09-17
ISIN US28617K1016
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://eledon.com
Цена ао 3.37
Change price per day: 0% (2.98)
Change price per week: +9.96% (2.71)
Change price per month: -18.36% (3.65)
Change price per 3 month: -19.68% (3.71)
Change price per half year: +1.71% (2.93)
Change price per year: +86.25% (1.6)
Change price per 3 year: -11.57% (3.37)
Change price per 5 year: +1 046.15% (0.26)
Change price per year to date: -29.38% (4.22)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 17.01 1
P/E 0 0
EV/EBITDA -0.7845 0
Total: 0.875

Efficiency

Title Value Grade
ROA, % -23.29 0
ROE, % -35.05 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0224 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 252.28 10
Yield EPS, % -99.54 0
Total: 5.4
More

Institutions Volume Share, %
BVF Inc. 4326710 17.88
Armistice Capital, LLC 1824000 7.54
Vanguard Group Inc 674520 2.79
Woodline Partners LP 603993 2.5
Ensign Peak Advisors, Inc 443001 1.83
CM Management, LLC 234803 0.97
Geode Capital Management, LLC 176039 0.73
Royal Bank of Canada 158207 0.65
Renaissance Technologies, LLC 61973 0.26
JMAC Enterprises LLC 58041 0.24



Head Job title Payment Year of birth
Dr. David-Alexandre C. Gros M.D., Ph.D. CEO & Non Independent Director 807.96k 1972 (53 years)
Dr. Steven N. Perrin Ph.D. President, Chief Scientific Officer & Non Independent Director 603.9k 1966 (59 years)
Mr. Paul Sean Little Chief Financial Officer 611.71k 1965 (60 years)
Mr. John Herberger Vice President of Technical Operations N/A
Mr. Bryan E. Smith J.D. General Counsel, Corporate Secretary & Chief Compliance Officer 377.14k 1980 (45 years)
Dr. David Hovland Ph.D. Chief Regulatory Officer N/A
Dr. Eliezer Katz F.A.C.S., FACS, M.D. Chief Medical Officer N/A

Address: United States, Irvine. CA, 19900 MacArthur Boulevard - open in Google maps, open in Yandex maps
Website: https://eledon.com